Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Open-Label Follow-up of Sotatercept in Pulmonary Arterial Hypertension (MK-7962-004 / A011-12)
2023-509138-21-00Phase 3Completed
- Sponsor
- Acceleron Pharma Inc.
- Start
- Aug 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 28
01
Overview
Phase 3, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Acceleron Pharma Inc. Primary endpoints: Adverse events, Anti-drug antibodies and 3 more. Started Aug 2021; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-509138-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509138-21-00.